UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant  ☒                            Filed by a party other than the Registrant  ☐

Check the appropriate box:

PerkinElmer, Inc.

(Name of Registrant as Specified In Itsin its Charter)

Not applicable.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

March 13, 201910, 2021

Dear Shareholder:

We cordially invite you to attend the 20192021 annual meeting of shareholders of PerkinElmer, Inc. to be held on Tuesday, April 23, 2019,27, 2021, at 8:00 a.m. atAs a result of the continued public health restrictions on in-person gatherings given the coronavirus pandemic, and to promote the health and safety of our corporate offices at 940 Winter Street, Waltham, Massachusetts.shareholders, directors and employees, the format of the meeting will be virtual only.

The attached notice of annual meeting and proxy statement containcontains information about matters to be considered at the virtual annual meeting. As described in those materials, you are entitled to participate in the annual meeting andvia live webcast at www.virtualshareholdermeeting.com/PKI2021 if you were a map with directions toshareholder as of the close of business on March 1, 2021, the record date for the annual meeting, or hold a legal proxy for the meeting is on the back cover of the proxy statement. Only shareholdersprovided by your broker, bank or nominee. To vote electronically and their proxies are invited to attendsubmit questions during the annual meeting.meeting, you must enter the control number included on your proxy card, voting instruction form or notice. On or about March 10^th, we mailed to our shareholders of record, other than those who previously requested e-mail or paper delivery of proxy materials, a notice of Internet availability containing their control number, instructions on how to access our 2021 proxy statement and 2020 annual report to shareholders through the Internet, and how to vote through the Internet. Beneficial owners received a similar notice from their broker, bank or other nominee.

Your vote is important regardless of the number of shares you own. Whether or not you plan to attend the virtual meeting, I hope you will review carefully the attached proxy materials and vote as soon as possible. We urge you to complete, sign and return the enclosed proxy card, or to vote over the Internet or by telephone, so that your shares will be represented and voted at the annual meeting.

Thank you for your continued support of PerkinElmer.

Notice of Annual Meeting

and

Proxy Statement 20192021

PerkinElmer, Inc.

Corporate Offices

940 Winter Street

Waltham, Massachusetts 02451

To the Shareholders of PerkinElmer, Inc.:

The annual meeting of the shareholders of PerkinElmer, Inc. will be held at the company’s corporate offices, located at 940 Winter Street, Waltham, Massachusetts 02451,via a live webcast in virtual meeting format, on Tuesday, April 23, 2019,27, 2021, at 8:00 a.m., to consider and act upon the following:

Our board of directors has no knowledge of any other business to be transacted at the meeting.

Our board of directors has fixed the close of business on February 25, 2019March 1, 2021 as the record date for the determination of shareholders entitled to receive this notice and to vote at the meeting.

All shareholders are cordially invited to attend the virtual annual meeting.

March 13, 201910, 2021

RETURN ENCLOSED PROXY CARD OR VOTE BY INTERNET OR TELEPHONE

Whether or not you expect to attend this virtual meeting, please complete, date, and sign the enclosed proxy card and mail it promptly in the enclosed envelope. No postage is required if mailed in the United States. Prompt response is important, and your cooperation will be appreciated. If the envelope is lost, please return the card to: Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, New York 11717. Alternatively, you may submit your vote via the Internet or telephone by following the instructions set forth on the enclosed proxy card.

To assist you in reviewing the proxy statement for the PerkinElmer, Inc. 20192021 annual meeting of shareholders, we call your attention to the following information about the virtual annual meeting, our corporate governance framework and key facts regarding our executive compensation structure and practices. For more complete information, please review the PerkinElmer, Inc. proxy statement in its entirety, as well as our annual report to shareholders for the fiscal year ended December 30, 2018.January 3, 2021.

Annual Meeting of Shareholders

Meeting Agenda and Voting Recommendations

PerkinElmer •20192021 Proxy Statement    i

Director Nominees

The following table provides summary information about the eight directors nominated for election as directors for terms of one year each:

Corporate Governance Highlights

The following table summarizes our board structure and key elements of our corporate governance framework:

ii    PerkinElmer •20192021 Proxy Statement

Fiscal 2018 Compensation2020 Business Highlights

2018 Compensation Structure.    The structureOur team continued to deliver on our long-term strategy in 2020, leading to a year of strong financial results. Our positive performance was the result of both strategic investments and execution on operational initiatives. Highlights of our executive compensation program supports our business strategy by drivingtop-line results while remaining focused on profitability and increased operating productivity, and by creating sustainable market positions for our products, technology and services. This is evidenced by the significant percentage of our executive compensation package tied to short- or long-term performance. Not including the cost of benefits, in 2018 our Chief Executive Officer had 86% of his target compensation at risk, and on average our other named executive officers had 76% of their target compensation at risk (that is, subject to eitherfiscal year 2020 performance requirements and/or service requirements).

2018 Target Total Compensationinclude:

Chief Executive Officer Global ICP 14% Base 14% LTIP 72% Other Named Executive Officers (Average) Global ICP 18% Base 24% LTIP 58% LTIP (long-term incentive plan) Global ICP (short-term incentive plan) Base Salary

Overall,

A reconciliation of our GAAP results to the non-GAAP financial measures set forth above, including adjusted revenue, adjusted revenue growth, organic revenue growth and adjusted EPS and adjusted EPS growth from continuing operations, can be found in Appendix A to this proxy statement.

The Company’s response to the COVID-19 pandemic

As the pandemic unfolded in the early months of 2020, our leadership team and our board responded in a number of ways to enable strong business performance as well as maintain employee morale and retain key employees. Foremost in our efforts was a focus on the health and safety of our employees. Highlights of our response to the COVID-19 pandemic included:

PerkinElmer • 2021 Proxy Statement    iii

Environmental, Social and Governance Principles

As a good corporate citizen, we believe it is our responsibility to drive our mission of innovating for a healthier world. By being mindful of our environmental impacts and by developing products to sustain the health and safety of people and the environment, we ensure that the way we do business is as meaningful as the solutions we provide. We strive to consistently deliver value to our customers, invest in our employees, deal fairly and ethically with all stakeholders, and create better outcomes in the communities where we live and work.

We recently refreshed PerkinElmer’s corporate social responsibility pillars of Governance, Sustainability, and Culture, Community & Our People. The intent is to better reflect how we approach global environmental, social, and governance (ESG) principles and the unique characteristics that make PerkinElmer the kind of company people want to work for, do business with, invest in, and rely on.

By creating healthier families, improving the quality of life, and sustaining the well-being and longevity of people globally, we believe PerkinElmer’s mission is essential. But we cannot do it alone. We encourage all of our stakeholders to join with us in adopting a new mindset based on the power of partnerships, a shared purpose, and a fierce passion. This way, what we can achieve today will result in a brighter tomorrow.

Governance

Sound corporate governance is a crucial component of our guiding business philosophy. As a global organization, we are committed to conducting business with customers, business partners, shareholders, and employees according to our high standards of ethics and transparency, and in compliance with the law.

Sustainability

We strive to infuse sustainability into all aspects of our business and recognize that each of our sites has the responsibility to research, source, and execute safety, resource-efficiency, and energy-saving activities to reduce the environmental impacts of our operations.

Culture, Community & Our People

At PerkinElmer, our mission extends beyond just the solutions we provide. Our mission also applies to how we support local organizations and communities. Similarly, our work to help improve lives begins with the environment we create for our own people. Whether on the manufacturing floor, in the lab, out in the field with customers or within the walls of our offices, each of our 14,000 employees plays a unique role in helping us achieve our goals. Our goal is for all employees to have a strongpay-for-performance culture and have implemented compensationequal access to resources, programs, and practicesnetworks that enable a differentiated employee experience.

As a global company, we understand that our ability to operate in a multicultural world is critical to our long-term sustainability. We are committed to creating alignment withan environment where the interestscultures, experiences, and perspectives of our shareholders. Further information regardingemployees are embraced and respected. We provide equal employment opportunities that allow all individuals to maximize their capabilities and enrich the value of our executive compensation programs is foundorganization, regardless of race, national origin, religion, gender, sexual orientation, age, disability, or veteran status. Our diversified workforce fuels the innovative insights we provide to our customers and global communities.

iv    PerkinElmer • 2021 Proxy Statement

We also seek to provide our employees with meaningful learning opportunities to help grow their capabilities and careers. We provide learning through many channels and in many formats, including formal (classroom-based, blended learning solutions, digital learning) and informal, on-the-job learning. We are also dedicated to our employees’ professional development, with a pivotal component of our annual performance review and goal-setting process focused on providing employees with constructive and actionable feedback, as well as management support and engagement in the proxy statement under “Compensation Discussioncreation and Analysis” beginning on page 24.completion of development goals. Additionally, we seeded funding into the PerkinElmer Foundation to serve as a charitable matching vehicle for future donations from our employees to qualified organizations.

Finally, we continue to engage our colleagues around our core values: Create Better Solutions for the Customer Today; Passion for People; Us Before Me, We Are a Team; Do the Right Thing Always; We Take Ownership and Get it Done. These principles both guide us and remind us that the way we achieve our goals is just as important as the goals themselves.

PerkinElmer •20192021 Proxy Statement    iiiv

General Information

Why am I receiving these materials?

PerkinElmer, Inc., also referred to as we, us, the Company or PerkinElmer, has prepared this proxy statement to provide our shareholders with information pertaining to the matters to be voted on at our annual meeting of shareholders to be held on Tuesday, April 23, 201927, 2021 at 8:00 a.m., as a virtual meeting via live webcast at our corporate offices, located at 940 Winter Street, Waltham, Massachusetts 02451,www.virtualshareholdermeeting.com/PKI2021, and at any adjournment of that meeting. The date of this proxy statement is March 13, 2019,10, 2021, the approximate date on which we first sent or provided the proxy statement and form of proxy to our shareholders.

Our board of directors has fixed the close of business on February 25, 2019March 1, 2021 as the record date for determining the shareholders entitled to receive notice of, and to vote their shares at, the meeting. On the record date, there were 110,802,896112,061,794 shares of our common stock outstanding and entitled to vote. Each share of common stock carries the right to cast one vote on each of the proposals presented for shareholder action, with no cumulative voting.

Your vote is important no matter how many shares you own. Please take the time to vote. Take a moment to read the instructions below. Choose the way to vote that is easiest and most convenient for you and cast your vote as soon as possible.

IfHow can I vote my shares at, and participate in, the virtual annual meeting?

This year’s annual meeting will be held entirely online due to the continued public health restrictions on in-person gatherings caused by the coronavirus pandemic, to promote the health and safety of our shareholders, directors and employees and to allow greater participation. Shareholders may participate in the annual meeting by visiting the following website: www.virtualshareholdermeeting.com/PKI2021. You will need the 16-digit control number included on your notice, on your proxy card or on the instructions that accompanied your proxy materials. Shares held in your name as the shareholder of record may be voted electronically during the annual meeting. Shares for which you are the “record holder”beneficial owner but not the shareholder of your shares, meaningrecord may also be voted electronically during the annual meeting. However, even if you plan to attend the virtual meeting, the Company recommends that you ownvote your shares in advance, so that your own name andvote will be counted if you later decide not throughto attend the meeting. Shareholders attending the meeting as a bankguest are not able to vote or brokerage firm, you mayask questions during the meeting.

How can I vote in one of four ways:my shares without attending the virtual annual meeting?

(1) You may vote over the Internet. If you have Internet access, you mayTo vote your shares from any location inwithout attending the world by followingvirtual meeting, please follow the “Vote by Internet” instructions on the enclosed proxy card.

(2) You may vote by telephone. You may vote your shares by following the “Vote by Telephone” instructions on the enclosed proxy card.

(3) You may vote by mail. You may vote by completing and signing the proxy card delivered with this proxy statement and promptly mailing it in the enclosed postage-paid envelope. The shares you own will be voted according to your instructionsfor Internet or telephone voting on the proxy card, you mail.voting instruction form or notice. If you signreceived your proxy materials by mail, you may also vote by signing and return thesubmitting your proxy card and returning it by mail, if you are the shareholder of record, or by signing the voter instruction form provided by your bank or broker and returning it by mail, if you are the beneficial owner but do not give any instructions on a particular matter described in this proxy statement, the shareholder of record. This way your shares you own will be voted in accordance with the recommendations of our board of directors. The board of directors recommends thatrepresented whether or not you vote FOR Proposal No. 1are able to elect eight nominees for director for terms of one year each, FOR Proposal No. 2 to ratify the selection of Deloitte & Touche LLP as PerkinElmer’s independent registered public accounting firm for the current fiscal year, FOR Proposal No. 3 to approve, on anon-binding advisory basis, our executive compensation, and FOR Proposal No. 4 to approve the PerkinElmer, Inc. 2019 Incentive Plan.

(4) You may vote in person. If you attend the meeting, you may vote by delivering your completed proxy card in person or you may vote by completing a ballot. Ballots will be available at thevirtual meeting.

What if I want to change my vote?

You canmay change your vote and revoke your proxy at any time before it is exercised, which can be done by voting your shares online while virtually attending the polls close at theannual meeting, by doing any one ofdelivering a new proxy or by notifying the following:

Your attendance at the meeting alone will not revoke your proxy.

Note that ifregistered holder. If voting by Internet or telephone, you may change your vote and revoke your proxy up untilto 11:59 p.m. Eastern Time on the day before the meeting by following the “Vote by Internet”instructions on your proxy card or “Vote by Telephone” instructions, respectively, on the enclosed proxy card.voting instruction form.

PerkinElmer •20192021 Proxy Statement    1

If the shares you own are held in “street name” by a bank, broker or other nominee record holder, which, for convenience, we collectively refer to in this proxy statement as brokerage firms, your brokerage firm, as the record holder of your shares, is required to vote your shares according to your instructions. In order to vote your shares, you will need to follow the directions your brokerage firm provides you. Many brokerage firms also offer the option of providing for voting over the Internet or by telephone, instructions for which, if available, would be provided by your brokerage firm on the vote instruction form that it delivers to you. Under the current rules of the New York Stock Exchange, or NYSE, if you do not give instructions to your brokerage firm, it will still be able to vote your shares with respect to certain “discretionary” items, but will not be allowed to vote your shares with respect to certain“non-discretionary” items. The ratification of Deloitte & Touche LLP as our independent registered public accounting firm (Proposal No. 2) is considered to be a discretionary item under the NYSE rules, and your brokerage firmWhat proposals will be able to votevoted on that item even if it does not receive instructions from you, as long as it holds your shares in its name. The election of directors (Proposal No. 1), the approval of our executive compensation program (Proposal No. 3), and the approval of the PerkinElmer, Inc. 2019 Incentive Plan are all“non-discretionary” items. If you return an instruction card to your brokerage firm but do not instruct your brokerage firm on how to vote with respect to Proposal No. 1, No. 3 or No. 4, your brokerage firm will not vote with respect to the proposal(s) for which you did not give instructions, and your shares will be counted as “brokernon-votes” with respect to those proposals. “Brokernon-votes” are shares that are held in “street name” by a brokerage firm that indicates on its proxy that it does not have or did not exercise discretionary authority to vote on a particular matter.

If your shares are held in street name, you must bring an account statement or letter from your brokerage firm showing that you are the beneficial owner of the shares as of the record date (February 25, 2019) in order to be admitted to the meeting on April 23, 2019. To be able to vote your shares held in street name at the meeting, you will need to obtain a proxy card from the holder of record.

This proxy is solicited on behalf of our board of directors.We will bear the expenses connected with this proxy solicitation. We expect to pay brokers, nominees, fiduciaries, and other custodians their reasonable expenses for forwarding proxy materials and annual reports to principals and obtaining their voting instructions. We have engaged Georgeson Inc. of New York, New York to assist us in soliciting proxies from brokers, nominees, fiduciaries, and custodians, and will pay Georgeson $25,000 plusout-of-pocket expenses for its efforts. In addition to the use of the mails, our directors, officers, and employees may, without additional remuneration, solicit proxies in person or by use of other communications media.

We previously mailed to shareholders, or are providing with this proxy statement, our annual report to shareholders for 2018. The annual report is not part of, or incorporated by reference in, this proxy statement.

Important Notice Regarding the Availability of Proxy Materials for

the Annual Meeting of Shareholders to Be Held on April 23, 2019:

This proxy statement and the 2018 annual report to shareholders are available at

www.proxyvote.com for viewing, downloading and printing.

A copy of our Annual Report on Form10-K for the fiscal year ended December 30, 2018 as filed with the Securities and Exchange Commission, except for exhibits, will be furnished without charge to any shareholder upon written or oral request to PerkinElmer, Inc., 940 Winter Street, Waltham, Massachusetts 02451, Attention: Investor Relations, Telephone:(800) 762-4000.

Householding of Annual Meeting Materials

Some brokerage firms may be participating in the practice of “householding” proxy statements, annual reports and notices of Internet availability of proxy materials. This means that only one copy of

2    PerkinElmer •2019 Proxy Statementvirtual meeting?

Many brokerage firms also offer the option of providing for voting over the Internet or by telephone, instructions for which, if available, would be provided by your brokerage firm on the voting instruction form that it delivers to you. Under the current rules of the New York Stock Exchange, or NYSE, if you do not give instructions to your brokerage firm, it will still be able to vote your shares with respect to certain “discretionary” items, but will not be allowed to vote your shares with respect to certain “non-discretionary” items. The ratification of Deloitte & Touche LLP as our independent registered public accounting firm (Proposal No. 2) is considered to be a discretionary item under the NYSE rules, and your brokerage firm will be able to vote on that item even if it does not receive instructions from you, as long as it holds your shares in its name. The election of directors (Proposal No. 1) and the approval of our executive compensation program (Proposal No. 3) are both “non-discretionary” items. If you return an instruction card to your brokerage firm but do not instruct your brokerage firm on how to vote with respect to these items, your brokerage firm will not vote with respect to the proposal(s) for which you did not give instructions, and your shares will be counted as “broker non-votes” with respect to those proposals. “Broker non-votes” are shares that are held in “street name” by a brokerage firm that indicates on its proxy that it does not have or did not exercise discretionary authority to vote on a particular matter.

Who is paying for this solicitation?

This proxy is solicited on behalf of our board of directors. We will bear the expenses connected with this proxy solicitation. We expect to pay brokers, nominees, fiduciaries, and other custodians their reasonable expenses for forwarding proxy materials and annual reports to principals and obtaining their voting instructions. We have engaged Georgeson Inc. of New York, New York to assist us in soliciting proxies from brokers, nominees, fiduciaries, and custodians, and will pay Georgeson approximately $25,000 plus out-of-pocket expenses for its efforts. In addition to the use of the mails, our directors, officers, and employees may, without additional remuneration, solicit proxies in person or by use of other communications media.

How can I view or request proxy materials?

We previously mailed to shareholders, or are providing with this proxy statement, our annual report to shareholders for 2020. The annual report is not part of, or incorporated by reference in, this proxy statement.

Important Notice Regarding the Availability of Proxy Materials for

the Annual Meeting of Shareholders to Be Held on April 27, 2021:

This proxy statement and the 2020 annual report to shareholders are available at

www.proxyvote.com for viewing, downloading and printing.

Votes RequiredA copy of our Annual Report on Form 10-K for the fiscal year ended January 3, 2021 as filed with the Securities and Exchange Commission, except for exhibits, will be furnished without charge to any shareholder upon written or oral request to PerkinElmer, Inc., 940 Winter Street, Waltham, Massachusetts 02451, Attention: Investor Relations, Telephone: (800) 762-4000.

How will materials be delivered to beneficial owners at the same address?

Some brokerage firms may be participating in the practice of “householding” proxy statements, annual reports and notices of Internet availability of proxy materials. This means that only one copy of these documents may have been sent to multiple shareholders in your household. We will promptly deliver a separate copy of any of these documents to you if you request one by writing or calling as follows: PerkinElmer, Inc., 940 Winter Street, Waltham, Massachusetts 02451, Attention: Investor Relations, Telephone: (800) 762-4000. If you want to receive separate copies of our annual report and proxy statement in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your brokerage firm, or you may contact us at the above address and phone number.

PerkinElmer • 2021 Proxy Statement    3

What are the voting standards?

A majority in interest of all PerkinElmer common stock issued, outstanding and entitled to vote on each proposal being submitted for shareholder action at the meeting constitutes a quorum with

PerkinElmer •2019 Proxy Statement    3

Our charter andBy-laws provide that the shareholders or the board of directors will determine the number of directors to serve on our board as not fewer than three noror more than thirteen. Our nominees for directors are each elected for aone-year term at the annual meeting of shareholders in accordance with our charter andBy-laws. We currently have nineeight directors, all of whose terms expire at this meeting. Our directors have voted to reduce the size of our board to eight members, effective as of the 2019 annual meeting of shareholders. Mr. Lopardo will not be standing forre-election to our board of directors at the 2019 annual meeting of shareholders.

Our board of directors, upon the recommendation of its nominating and corporate governance committee, has nominated the following persons for election as directors forone-year terms, each expiring at the annual meeting of shareholders to be held in 2020.2022. All of the nominees are currently directors of PerkinElmer and were elected by our shareholders at the 20182020 annual meeting.

PerkinElmer •20192021 Proxy Statement    5

Director Qualification Matrix

The members of the board have a diversity of experience and a wide variety of backgrounds, skills, qualifications and viewpoints that strengthen their ability to carry out their oversight role on behalf of our shareholders. The following matrix is provided to illustrate the knowledge, skills and experience of the nominees for director to serve on our board. The matrix does not encompass all of the knowledge, skills and experience of our directors, and the fact that a particular knowledge, skill or experience is not listed does not mean that a director does not possess it. In addition, the absence of a particular knowledge, skill or experience with respect to any of our directors does not mean the director in question is unable to contribute to the decision-making process in that area. However, a mark indicates a specific area of focus or expertise that the director brings to our board. More information on each director’s qualifications and background is included in the director biographies on the following pages. We regularly review the attributes required of board members in order to better facilitate the Company’s long-term goals, operational performance, corporate culture and to promote diversity and inclusiveness.

OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE “FOR”

ELECTING EACH OF THE EIGHT NOMINEES NAMED ABOVE FOR TERMS OF ONE YEAR EACH.

The persons named as proxies on the proxy card will vote shares represented by a proxy for the election of the eight nominees for terms of one year each, unless the shareholder instructs otherwise on their proxy card. Our board of directors knows of no reason why any nominee should be unable or unwilling to serve. However, if that becomes the case, the persons named as proxies on the proxy card may vote to elect a substitute. In no event will shares represented by proxies be voted for more than eight nominees.

To apprise you of their qualifications to serve as directors, we include the following information concerning each of the director nominees. The qualifications presented include information each nominee has provided to us regarding age, current positions held, principal occupation and business experience for the past five years, as well as the names of other publicly held companies of which the nominee currently serves as a director or has served as a director during the past five years. In addition to the information presented regarding each nominee’s specific experience, qualifications, attributes and skills that led the nominating and corporate governance committee to recommend that our board nominate these individuals, our board believes that all of the nominees have a reputation for honesty, integrity and adherence to high ethical standards. The nominating and corporate governance committee also believes that the nominees possess the willingness to engage management and each other in a positive and collaborative fashion, and are prepared to make the significant commitment of time and energy to serve on our board and its committees.

PETER BARRETT:BARRETT, PhD:    Age 66;68; Principal Occupation: Partner, Atlas Venture, a venture capital fund based in Cambridge, Massachusetts. Director of PerkinElmer since 2012. Chair of the compensation and benefits committee and member of the nominating and corporate governance committee.

Mr.Dr. Barrett joined Atlas Venture, an early stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group. Previously, he was aco-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Prior to that, Mr.Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. He currently serves as the Chairman of Zafgen,Synlogic, Inc. and Synlogic,is a board member of Larimar Therapeutics, Inc., both of which are publicly traded, as well as a board member of several privately held companies, and during the past five years has served as a director of Akela Pharma, Inc., Alnylam Pharmaceuticals, Inc. and Momenta Pharmaceuticals, Inc. Mr.companies. Dr. Barrett is also a senior fellow at the Harvard Business School. Mr.Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Doctoral degree in analytical chemistry from Northeastern University.

Mr.Dr. Barrett brings to the board more than three decades of experience in the life sciences industry, including leadership positions both as a senior executive and as an institutional investor. These roles have allowed him to develop expertise in the deployment of strategic growth initiatives within the industry. His service onas chair and as a member of the boards of other companies, both publicly and privately held, enables him to assist our board in the performance of its governance obligations.

SAMUEL R. CHAPIN:    Age 61;63; Principal Occupation: Retired Executive Vice Chairman, Bank of America Merrill Lynch, a worldwide financial institution. Director of PerkinElmer since 2016. Chair of the audit committee and member of the finance committee.

Mr. Chapin was appointed Executive Vice Chairman of Global Corporate & Investment Banking at Bank of America Merrill Lynch in February 2010, where he was responsible for managing relationships with some of the firm’s largest clients. Mr. Chapin retired from the firm as of June 30, 2016. Mr. Chapin has worked on a broad range of financings and strategic advisory assignments totaling more than $500 billion, and has been named Investment Banker of the Year by Investment Dealers’ Digest. Mr. Chapin was named Vice Chairman of Merrill Lynch & Co., Inc. in September 2003 and was a member of the firm’s executive Operating Committee. From 2001 to 2003, he was Senior Vice

PerkinElmer • 2021 Proxy Statement    7

President and Head of the Global Investment Banking division. Mr. Chapin first joined Merrill Lynch &

6    PerkinElmer •2019 Proxy Statement

Mr. Michas was named Non-Executive Chairman of the board as of December 30, 2019. He brings to our board, and to the position of Non-Executive Chairman, many years of private equity experience across a wide range of industries, and a successful record of managing investments in public companies. Mr. Michas also brings extensive transactional expertise, including mergers and acquisitions, IPOs, debt and equity offerings, and bank financing. This expertise is utilized through his position as a member of the finance committee of our board, allowingallows Mr. Michas to provide our board with valuable insight on trends in global debt and equity markets, and the impact of such trends on the capital structure of the Company. We also benefit from the corporate governance knowledge developed by Mr. Michas in his board roles with other public companies, including his service as a board chairman, a lead director, a board chairman, and a member of the compensation, governance, audit, finance and executive committees of such companies. Mr. Michas’ thorough knowledge of the Company and his thorough understanding ofcurrent and past service on the role of boards of directors qualifyother public companies make him uniquely qualified to serve on our board and as our Lead Director.Non-Executive Chairman.

PATRICK J. SULLIVAN:PRAHLAD R. SINGH, PhD:    Age 67;56; Principal Occupation: RetiredPresident and Chief Executive Officer and Chairman of Insulet Corporation, an innovative medical device company based in Acton, Massachusetts.PerkinElmer. Director of PerkinElmer since 2008. Member of the compensation and benefits committee and the nominating and corporate governance committees.2019.

Mr. Sullivan served as theDr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and Chairmanappointed to our board of directors in 2019. Previously, Dr. Singh was the President and Chief Operating Officer of the BoardCompany since January 2019. Dr. Singh joined PerkinElmer as the President of Insulet Corporation, a publicly traded medical device company, from Octoberour Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 through 2018, having previously served asand Executive Vice President Chief Executive Officer and Director since September 2014.in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Mr. Sullivan was the Executive ChairmanDr. Singh held senior executive level roles in strategy, business development and a director of Hologic from its merger with Cytyc Corporationmergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in October 2007 until May 2008. Mr. Sullivan previously served Cytyc in a number of seniorhis career, he held leadership positionsroles of increasing responsibility beginning in 1991,at DuPont Pharmaceuticals and culminating in being named Chief Executive Officer in 1994subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Chairman in 2002. Prior to joining Cytyc, Mr. Sullivan was employed in key senior marketing positions for five years by Abbott Laboratories, a diversified healthcare company, and was a consultant with McKinsey & Company, an international management consulting firm. In addition to his past service as a director of Insulet Corporation, Mr. Sullivan currently serves on the board of several privately held companies and was a member of the board of directors ofGen-Probe Incorporated until its acquisition by Hologic, Inc. in 2012. HeMiddle East region. Dr. Singh holds a Bachelor

8    PerkinElmer •2019 Proxy Statement

the University of Bordeaux. He is a board member for both the N-Lorem Foundation and the Early Detection of Neurodegenerative Diseases (EDoN). He also sits on the advisory board of Tsinghua University School of Pharmaceutical Sciences and is a member of the MIT Presidential CEO Advisory Board. Mr. Vounatsos received his Certificate of Clinical and Therapeutic Synthesis in Medicine from the Université Victor Segalen, Bordeaux II, France, and his Master of Business Administration degree from the HEC School of Management in Paris.

Mr. Vounatsos brings to our board significant knowledge and broad-based experience with respect to the biotechnology, healthcare and pharmaceutical industries, as well as comprehensive global leadership expertise resulting from decades of service as an executive in the pharmaceutical industry and his unique academic perspective from his time studying both medicine and business. Mr. Vounatsos also brings valuable insight and guidance through both his current and previous serviceleadership skills gained as the chief executive officer of publicly traded companies as well as his service on the boards of other publicly traded companies, including as chairman. He possesses broad expertise in strategic planning, business development and global marketing. Mr. Sullivan’s background in diagnostics and women’s health allows him to bring to our board significant knowledge of these important issues and their potential future impact on the Company.a publicly-traded multinational organization.

FRANK WITNEY, PhD:    Age 65;67; Principal Occupation: Former Chief Executive Officer, Affymetrix, Inc., a leading provider of microarray technology; Director of PerkinElmer since 2016. Member of the audit and compensation and benefits committees.committee.

Dr. Witney most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company from 2009 to 2011. Prior to that, Dr. Witney served as Executive Vice President and Chief Commercial Officer of Affymetrix from 2008 to 2009, following its acquisition of Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer from 2002 to 2008. He previously held the role of President of PerkinElmer’s Drug Discovery Tools division following PerkinElmer’s acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions atBio-Rad Laboratories beginning in 1983, leading that company’s efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation, as well as the Chairman of the Board of Gyros Protein Technologies AB, and a member of the board of RareCyte, Inc., Nexcelom Bioscience LLC, Emulate, Inc., Codex DNA and GenapSys, Inc.,Jumpcode Genomics, all of which are privately held, and is an Operating Partner at Ampersand Capital Partners.

Dr. Witney brings to our board deep market knowledge and over 30 years of leadership experience across the life sciences, diagnostics and analytical instruments industries, including as a chief executive officer and board member. Through this experience, he has developed expertise in several valued areas including strategic product development, business development and operational management.

PASCALE WITZ:    Age 52;54; Principal Occupation: Founder and Chief Executive Officer,President, PWH Advisors. Director of PerkinElmer since 2017. Member of the audit committee.

Ms. Witz has served as the Chief Executive OfficerPresident of PWH Advisors, a consulting servicesconsultancy firm foradvising healthcare and investment companies, since founding the firm in 2016. Previously, Ms. Witz served as a Member of the Executive Vice President, Diabetes & CardiovascularCommittee for Sanofi, S.A.S. A., from September 2015 through Mayto 2016 having formerly held the position ofas Executive Vice President, Global DivisionsDiabetes & Cardiovascular, and Strategic Development for Sanofi from July 2013.2013 to 2015 as Executive Vice President, Global Pharma and Consumer Healthcare divisions. Before joining Sanofi, Ms. Witz was employed in positions of increasing responsibility with GE Healthcare starting in 1996, most recently servingserved as the President and Chief Executive Officer of Medical DiagnosticsGE’s pharmaceutical diagnostics from March 2009 to 2013, a $2 billion integrated pharmaceutical business that encompassed research and development through June 2013.commercialization. Ms. Witz joined GE Healthcare in 1996, and held positions of increasing responsibility in Europe and the United States. Ms. Witz was previously employed with Becton Dickinson Pharmaceutical Systems from 1991 until 1996. Ms. Witz currently serves on the boards of Horizon Pharma Plc, Regulus Therapeutics, Inc. and Fresenius Medical Care AG & Co. KGaA, Regulus Therapeutics, Inc. and Horizon Therapeutics Plc, as well as several privately held companies, and

10    PerkinElmer • 2021 Proxy Statement

formerly served on the boards of Savenica SA and TESARO,Tesaro, Inc. She is also a director of thenot-for-profit French-American Foundation — France and the Global Alzheimer’s Platform Foundation. Ms. Witz received her Master of Business Administration degree from INSEAD, Fontainebleau, France and her Master of Science degree in biochemistry from the Institut National des Sciences Appliquées, de Lyon, France and her Master of Business Administration degree from INSEAD, Fontainebleau, France. She was also a doctoral student in molecular biology at the Centre National de la Recherche Scientifique, Strasbourg, France.

PerkinElmer •2019 Proxy Statement    9

Determination of Independence

Our common stock is listed on the New York Stock Exchange. Under current NYSE rules, a director of PerkinElmer qualifies as “independent” only if our board of directors affirmatively determines that the director has no material relationship with PerkinElmer, either directly or as a partner, shareholder or officer of an organization that has a relationship with PerkinElmer. Our board of directors evaluates the independence of our directors on an annual basis. In evaluating potentially material relationships, our board considers commercial, industrial, banking, counseling, legal, accounting, charitable and familial relationships, among others. Our board of directors has determined that none of Messrs. Barrett, Chapin, Lopardo, Michas, or Sullivan,Vounatsos, Ms. Witz, or Drs. Barrett, Grégoire or Witney, has a material relationship with PerkinElmer, and also that each of these directors is “independent” as determined under Section  303A.02(b) of the NYSE Listed Company Manual.

Director Candidates

Our shareholders may recommend director candidates for inclusion by the board of directors in the slate of nominees the board recommends to our shareholders for election. The qualifications of recommended candidates will be reviewed by the nominating and corporate governance committee. If the board determines to nominate a shareholder-recommended candidate and recommends his or her election as a director by the shareholders, the name will be included on our proxy card for the shareholders’ meeting at which his or her election is recommended.

Shareholders may recommend individuals for the nominating and corporate governance committee to consider as potential director candidates by submitting their names, together with appropriate biographical information and background materials, and a statement as to whether the shareholder or group of shareholders making the recommendation has beneficially owned more than 5% of our common stock for at least a year as of the date such recommendation is made. Materials should be mailed to the “PerkinElmer Nominating and Corporate Governance Committee” c/o Office of the General Counsel, PerkinElmer, Inc., 940 Winter Street, Waltham, Massachusetts 02451. The nominating and corporate governance committee will consider a proposed director candidate only if appropriate biographical information and background material are provided on a timely basis. The process followed by the nominating and corporate governance committee to identify and evaluate candidates may include requests to board members and others for recommendations, meetings from time to time to evaluate biographical information and background material relating to potential candidates, and interviews of selected candidates by members of the nominating and corporate governance committee and the board of directors. Assuming that appropriate biographical and background material are provided for candidates recommended by shareholders, the nominating and corporate governance committee will evaluate those candidates by following substantially the same process as outlined above, and applying substantially the same criteria, as for candidates submitted by board members.

Shareholders also have the right under ourBy-laws to nominate director candidates directly, without any action or recommendation on the part of the nominating and corporate governance committee or our board, by following the process for shareholder proposals for election of directors set forth in ourBy-laws and discussed in “Shareholder Proposals for 20202022 Annual Meeting of Shareholders,” below. Candidates nominated by shareholders in accordance with these procedures will not be included in our proxy card for the shareholder meeting at which his or her nomination is recommended.

12    PerkinElmer •20192021 Proxy Statement    11

Criteria and Diversity

In considering whether to recommend any candidate for inclusion in the board of directors’ slate of recommended director nominees, including candidates recommended by shareholders, the nominating and corporate governance committee will apply the criteria set forth in PerkinElmer’s corporate governance guidelines and such other factors as the committee deems appropriate. These criteria include the candidate’s experience, skills, and independence. In evaluating a candidate’s experience and skills, the nominating and corporate governance committee may also consider qualities such as an understanding of technologies, marketing, finance, regulation and public policy, and international issues. In evaluating a candidate’s independence, the nominating and corporate governance committee will consider the applicable independence standards of the NYSE and the Securities and Exchange Commission. The nominating and corporate governance committee will evaluate each director candidate in the context of the perceived needs of the board, the best interests of PerkinElmer and its shareholders, as well as our corporate governance guidelines which specify that the composition of the board should reflect diversity. Accordingly, the nominating and corporate governance committee seeks nominees with a broad range of experience, professions, skills and backgrounds. The nominating and corporate governance committee does not assign specific weights to particular criteria, and no particular criterion is necessarily applicable to all prospective nominees. We believe that the backgrounds and qualifications of the directors, considered as a group, should provide a significant composite mix of experience, knowledge and abilities that will allow our board to fulfill its responsibilities. Nominees are not discriminated against on the basis of race, religion, national origin, sexual orientation, disability or any other basis proscribed by law.

The nominating and corporate governance committee, as part of its annual assessment of board performance, reviews the diversity of experience, attributes and skills considered necessary for the optimal functioning of the board. The committee reviews the experience, attributes and skills currently represented on the board, as well as those areas where a change could improve the overall quality of our board and the ability of the board to perform its responsibilities. The committee then establishes those areas that could be the focus of a director search, if necessary. The effectiveness of the board’s diverse mix of experience, attributes and skills is reviewed as a component of the annual board self-assessment process.

Leadership Structure

Our board of directors selects a Chairman of the board by evaluating the criteria and using a process that the board considers to be in the best interests of the Company and its shareholders, pursuant to our corporate governance guidelines. Our board of directors does not have a fixed policy on whether the Chief Executive Officer and Chairman should be separate positions or whether the Chairman should be an employee ornon-employee. Currently, Mr. FrielMichas serves as ourNon-Executive Chairman and Dr. Singh serves as our Chief Executive Officer. Mr. Michas has been a member of our board since 2001 and has served as Non-Executive Chairman since December 30, 2019, having most recently served as our Lead Director. In addition to his years of experience on our board, Mr. Michas brings to the role a wealth of corporate governance knowledge developed in his board roles with other public companies. Dr. Singh joined the Company in 2014 and has held a number of senior leadership positions. Dr. Singh was elected to our board in 2019 and has served as our Chief Executive Officer since December 30, 2019. We believe that the Company will benefit from separating the roles of Chairman and Chief Executive Officer. Mr. Friel hasin-depth knowledge of the issues and opportunities facing the Company,Officer by allowing him to effectively develop agendas designedeach individual to focus the board’s time and attention on the most critical matters, while also leading the discussiontheir respective areas of those matters and ultimately the execution of the resulting strategic initiatives. The combined role promotes decisive leadership and clear accountability. Our corporate governance guidelines require that if the Chief Executive Officer is alsoresponsibility. As Non-Executive Chairman, then there should be a Lead Director elected annually by the board from the independent directors. The Chair of the nominating and corporate governance committee leads an annual process for electing a Lead Director. Mr. Michas currently serves as our Lead Director. TheMichas’ primary responsibilities include presiding at meetings of our board of directors, reviewing and assisting in setting the Lead Director include communication withagenda and schedule for meetings of our board of directors, advising the Chief Executive Officer,committee chairs in performing their responsibilities, initiating and chairing meetings of the independent directors, and counseling the Chief Executive Officer and directors as needed. Our board holds executive sessions of the independent directors preceding or following each regularly scheduled board meeting. We believe that the current leadership structure, which combines Mr. Friel’s two decadesthrough the combination of executive experience withDr. Singh’s knowledge of the Company in a variety of key leadership roles withas Chief

PerkinElmer • 2021 Proxy Statement    13

Executive Officer and Mr. Michas’ demonstrated understanding of the role played by boardsthe chair of a public company board of directors, allows the Chairman and Chief Executive Officer to set the overall

12    PerkinElmer •2019 Proxy Statement

is to oversee the management of the Company and, in so doing, serve the best interests of our Company and its shareholders. The board selects, evaluates and provides for the succession of our executive officers. It reviews and approves corporate objectives and strategies, and evaluates significant policies and proposed major commitments of corporate resources. It participates in decisions that have a potential major economic impact on PerkinElmer. Management keeps the directors informed of Company activity through regular written reports and presentations at board and committee meetings. The board participates in an annual self-evaluation process.

PerkinElmer •2019 Proxy Statement    13

environmental and social issues on the Company, and oversees the evaluation of the board. Our nominating and corporate governance committee also adopted and oversees our related party transactions policy. The current members of

14    PerkinElmer •2019 Proxy Statement

The audit committee is pleased to submit this report to the shareholders.

By the audit committee of the board of directors:

Samuel R. Chapin, Chair

Nicholas A. Lopardo

Frank WitneyMichel Vounatsos

Pascale Witz

Independent Registered Public Accounting Firm Fees and Other Matters

The following table presents the aggregate fees billed for services rendered by Deloitte & Touche LLP, the member firms of Deloitte & Touche Tohmatsu and their respective affiliates, in the identified categories for fiscal 20182020 and fiscal 2017:2019:

Audit Fees

These are fees related to professional services rendered in connection with the audit of our annual financial statements, the reviews of the interim financial statements included in each of our quarterly reports onForm 10-Q, and other professional services provided by our independent registered public accounting firm in connection with statutory or regulatory filings or engagements.

Audit-Related Fees

These are fees for assurance and related services that are reasonably related to performance of the audit and review of our financial statements, and which are not reported under “Audit Fees.” These services consisted primarily of audits of employee benefit plans, and for fiscal 2018, audit procedures performed related to divestitures, consultations regarding accounting and financial

16    PerkinElmer •2019, Proxy Statement

Tax Fees

These are fees billed for professional services for tax compliance, tax advice and tax planning services. Tax compliance services which relate to preparation of original and amended US and non-US corporate income tax returns (fees for which amounted to $191,000$221,000 in fiscal 20182020 and $198,000$245,000 in fiscal 2017)2019) and expatriate tax return preparation and assistance (fees for which amounted to $115,000$62,000 in fiscal 20182020 and $196,000$164,000 in fiscal 2017)2019) accounted for $306,000$283,000 of the total tax fees paid for in fiscal 20182020 and $394,000$409,000 of the total tax fees paid for in fiscal 2017.2019. Tax advice and planning services, including consultations on foreign transactions, assistance with tax audits and appeals, tax advice related to reorganizations, mergers and acquisitions, employee benefit plans and requests for rulings or technical advice from taxing authorities, amounted to $289,000$1,089,000 in fiscal 20182019 and $942,000$702,000 in fiscal 2017.2018.

All Other Fees

Fees paid or incurred for other services amounted to $5,000 in fiscal 20182019 and $5,000 in fiscal 2017.2018.

Audit Committee’sPre-approval Policy and Procedures

The audit committee of our board of directors has adopted policies and procedures for thepre-approval of audit andnon-audit services for the purpose of maintaining the independence of our independent registered public accounting firm. We may not engage our independent registered public accounting firm to render any audit ornon-audit service unless either the service is approved in advance by the audit committee, or the engagement to render the service is entered into pursuant to the audit committee’spre-approval policies and procedures. On an annual basis, the audit committee maypre-approve services that are expected to be provided to PerkinElmer by the independent registered public accounting firm during the following 12 months. At the time suchpre-approval is granted, the audit committee must (1) identify the particularpre-approved services in a sufficient level of detail so that our management will not be called upon to make a judgment as to whether a proposed service fits within thepre-approved services and (2) establish a monetary limit with respect to the totalpre-approved services, which limit may not be exceeded without obtaining furtherpre-approval under the policy.

Our management periodically provides the audit committee updates of proposed services forpre-approval. Any additional services which fall outside the scope of the annual service review process require advance approval by the audit committee. The audit committee may delegate to one or more designated members of the committee the authority to grantpre-approvals of permitted services, or classes of permitted services, to be provided by the independent registered public accounting firm. The decisions of a designated member topre-approve a permitted service are reported to the audit committee at its next regularly scheduled meeting. While controls have been established to identify all services rendered by the independent registered public accounting firm, the audit committee recognizes that there may be some “de minimis” services provided that, while considered permitted services, may not be identified asnon-audit services or reported immediately because of their “de minimis” nature. Such services may be approved prior to the completion of the audit by either the audit committee, or a designated member of the audit committee.

Certain Relationships and Policies on Related Party Transactions

The nominating and corporate governance committee of our board of directors has adopted written policies and procedures for the review of any transaction, arrangement or relationship in which PerkinElmer was or is to be a participant, and in which one of our executive officers, directors,

PerkinElmer •2019 Proxy Statement    17

interest, as determined by the committee. We refer to these transactions as “related party transactions.”

The policy calls for any proposed related party transaction to be reviewed and, if deemed appropriate, approved by our nominating and corporate governance committee. Whenever practicable, the review and approval will occur prior to entry into the transaction. If advance approval is not practicable, the committee will review, and, in its discretion, may approve the related party transaction. The policy also permits the Chair of the committee to review and, if deemed appropriate, approve proposed related party transactions that arise between committee meetings, in which case the Chair will report such transactions to the committee at its next meeting. Any related party transactions that are ongoing in nature will be reviewed annually. The committee will review and consider such information regarding the related party transaction as it deems appropriate under the circumstances.

The committee has determined that certain types of transactions, such as those excluded by the instructions to the Securities and Exchange Commission’s related person transaction disclosure rule, do not create a material direct or indirect interest on behalf of related parties and, therefore, are not related party transactions for purposes of this policy.

The committee may approve a related party transaction only if the committee determines that, under all of the circumstances, the transaction is in the best interest of PerkinElmer and its shareholders.

Anti-Hedging Policy

In addition to prohibiting trading while in possession of material non-public information, our securities trading policy prohibits all employees and members of our board from engaging in the following types of transactions with respect to our securities:

Also, our officers may not pledge any shares of our stock or hold company securities in a margin account.

18    PerkinElmer •20192021 Proxy Statement    19

Directors who are employees of PerkinElmer receive no additional compensation for their services as directors. Our compensation and benefits committee periodically reviews ournon-employee director compensation policies with the assistance of the compensation consultant, and makes recommendations to our nominating and corporate governance committee for that committee’s proposal to our board. The compensation consultant provides data on director compensation programs at a number of companies identified by the compensation and benefits committee and the compensation consultant as industry peers.

Our director compensation program is designed to provide a competitive level of compensation and to enable PerkinElmer to attract and retain highly-qualifiedhighly qualified board members. Annual compensation for ournon-employee directors consists of a cash retainer and equity compensation. Each of these components for 2018 is shown in the following table and explained further below.

2018 Director Compensation

Stock Options:2020 Director Compensation

Each of our non-employee directors held unvested restricted stock units as of January 3, 2021 as follows: Mr. Michas: 1,703; Mr. Chapin: 1,234; Dr. Barrett: 1,220; and Drs. Grégoire and Witney, Mr. Vounatsos and Ms. Witz: 1,166.

Our non-employee directors receive annual share grants which are not subject to restriction and therefore held no shares of restricted stock as of January 3, 2021. PerkinElmer common stock held by each of our non-employee directors as part of their compensation until January 2015. Stock options granted tonon-employee directors since 2005 vested in three equal annual installments beginning one year from the grant date and may be exercised for seven years from the grant date. All options granted tonon-employee directors have an exercise price equal to the fair market valueFebruary 15, 2021 is reported under “Beneficial Ownership of our stock on the date of grant. Directors who leave our board have three months after their departure to exercise their vested options, after which the options are cancelled, unless the departure is due to death or disability, in which case the options may be exercised for up to one year, or retirement from our board, in which case options may be exercised for three years after their departure. Directors qualify for retirement for purposes of our stock option awards after attaining both age 55 and ten years of service to the Company as a director.Common Stock” below.

New Director Compensation

Newnon-employee directors who serve for only a portion of the board service year receive a cash retainer and annual equity grants prorated to reflect the period he or she is anticipated to serve on our board during that year.

Deferred Compensation Plan

Non-employee directors have previously been provided with the opportunity to defer receipt of all or a portion of their cash retainer or stock awards into our 2008 Deferred Compensation Plan. In December 2010, the compensation and benefits committee amended this plan to eliminate new deferral elections from participants, including deferrals of director cash retainer or stock awards, for plan years beginning January 1, 2011 or later. None of thenon-employee directors had an active election to defer compensation during fiscal year 2018, and due to the plan amendment, no new deferral elections will be accepted. For more information about our deferred compensation program, see “Executive Compensation — 2018Non-Qualified Deferred Compensation —Non-Qualified Deferred Compensation Plan” below.

Business Travel Accident Insurance

Non-employee directors are provided with $250,000 of death benefit coverage under PerkinElmer’s business travel accident insurance policy which provides coverage while traveling on PerkinElmer business.

Director Stock Ownership Guidelines

Within five years of election to our board, we expect eachnon-employee director to own PerkinElmer stock with a fair market value equal to at least five times the annual cash retainer. For fiscal 2018,2020, this value was $450,000. Shares held in the deferred compensation plan are counted as owned$450,000 for purposes of these guidelines.all non-employee directors. As of February 15, 2019,16, 2021, all of our directors were in compliance with our stock ownership guidelines. See “Beneficial Ownership of Common Stock” below for the beneficial stock ownership of our directors.

Changes to Director Compensation

Our compensation and benefits committee periodically reviews and makes recommendations to the nominating and corporate governance committee regarding director compensation and director compensation guidelines.policies. As part of these periodic reviews, the compensation and benefits committee obtains data and analyses from an independent compensation consultant with respect to director compensation programs at a number of companies identified by the compensation and benefits committee and the compensation consultant as industry peers. Our director compensation, including annual retainers and stock and optionequity awards, is therefore subject to adjustment.

On January 23, 2020, our board approved changes to director compensation that went into effect on April 28, 2020, the date of our 2020 annual meeting of shareholders. The fair market value of the annual RSU grant was increased from $75,000 to $85,000, and the annual additional cash retainer for the Chair of the compensation and benefits committee was increased from $15,000 to $20,000. The compensation and benefits committee recommended the changes to our nominating and corporate governance committee, which then recommended the changes for approval by our board.

Compensation for the non-executive Chair role and changes to director compensation were determined based on a comprehensive analysis of non-employee director compensation at a group of

22    PerkinElmer • 2021 Proxy Statement

companies identified by the compensation and benefits committee’s compensation consultant and the compensation and benefits committee as our peers (which was the same group of peer companies used by the committee in its evaluation of executive compensation for fiscal 2019). These recommendations were intended to align our board compensation with market practice, which enables us to continue to attract and retain highly qualified board members. Please refer to “Compensation Discussion and Analysis — Compensation Policies — External Market Practices” for more information about the peer group used in connection with determining 2020 compensation.

PerkinElmer •20192021 Proxy Statement    2123

The following table shows the number of shares of our common stock beneficially owned on February 15, 201916, 2021 by (1) each of the directors and nominees for director individually, (2) each of the executive officers named in the Summary Compensation Table below, (3) any person known to us to own beneficially more than five percent of our outstanding common stock and (4) all executive officers and directors as a group. The beneficial ownership set forth below includes any shares that the person has the right to acquire within 60 days after February 15, 201916, 2021 through the exercise or conversion of any stock option or other right.